Edition:
United Kingdom

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,521.00GBp
4:55pm BST
Change (% chg)

56.50 (+1.27%)
Prev Close
4,464.50
Open
4,500.00
Day's High
4,545.50
Day's Low
4,490.50
Volume
1,467,853
Avg. Vol
2,071,389
52-wk High
4,662.00
52-wk Low
2,940.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.54
Market Cap(Mil.): £35,231.62
Shares Outstanding(Mil.): 908.51
Dividend: 3.85
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 66.92 30.92 33.69
EPS (TTM): 0.58 -- --
ROI: 1.15 14.76 14.30
ROE: 2.31 16.26 16.03

Takeda gets Japanese approval for $62 billion Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion (£47.3 billion) acquisition of Shire Plc , bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

9:33am BST

Takeda gets Japanese approval for $62 billion Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc , bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

9:27am BST

UPDATE 1-Takeda gets Japanese approval for $62 bln Shire purchase

Oct 18 Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

9:26am BST

Takeda gets Japan's approval for $62 bln Shire purchase

Oct 18 Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

8:05am BST

With Hemlibra, Roche seeks to break into tight hemophilia circle

ZURICH Swiss drugmaker Roche is breaking into hemophilia A treatment, a $10 billion (£7.70 billion) global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder.

03 Oct 2018

With Hemlibra, Roche seeks to break into tight hemophilia circle

ZURICH Swiss drugmaker Roche is breaking into hemophilia A treatment, a $10 billion global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder.

03 Oct 2018

Takeda's $62 billion Shire bid faces November 6 EU antitrust deadline

BRUSSELS EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion takeover of London-listed Shire Plc , the European Commission said on Friday.

28 Sep 2018

Takeda's $62 billion Shire bid faces Nov. 6 EU antitrust deadline

BRUSSELS EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion (47.5 billion pounds) takeover of London-listed Shire Plc , the European Commission said on Friday.

28 Sep 2018

Takeda's $62 bln Shire bid faces Nov. 6 EU antitrust deadline

BRUSSELS, Sept 28 EU antitrust regulators will decide by Nov. 6 whether to allow Japanese drugmaker Takeda Pharmaceutical's $62-billion takeover of London-listed Shire Plc, the European Commission said on Friday.

28 Sep 2018

Deal-making spree keeps investors upbeat about European M&A revival

MILAN, Sept 26 The $40 billion takeover of British broadcaster Sky and other new deals in Europe have broken a summer lull to bolster investor optimism over an M&A revival in the region.

26 Sep 2018

Earnings vs. Estimates